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ABSTRACT 
 
 
           The objective of this project was to develop new controlled drug delivery systems using 
nanomeric particles and characterize the delivery of drugs into cells in real time by digital 
fluorescence imaging microscopy techniques. The project is based on the idea that it could be 
possible to improve efficacy of drug molecules when encapsulated in nanometer-sized particles.  
Due to their small dimensions the particles could permeate through cells and tissues and even 
through the blood brain barrier.  
The anti-cancer drug Doxorubicin was encapsulated into biodegradable Poly (DL-lactide-
co-glycolide) (PLGA) nanoparticles by simple nanoprecipitation method.  The small size of 
these particles (<200nm) could be beneficial to realize passive tumor-targeted drug delivery 
through enhanced permeability and retention (EPR) effects. These drug-containing particles 
showed a sustained release profile. Fluorescence images indicated that these particles can be 
internalized by human breast cancer MCF-7 cells by non-specific endocytosis.  The bioactivity 
of the drugs was also tested against cell culture. The results indicated that DXR-loaded PLGA 
nanoaprticles could be used to deliver Doxorubicin into breast cancer cells. 
As the second approach, a novel silica nanoparticles-based stimuli-responsive drug 
delivery system has been developed. The feasibility of these unique carriers was demonstrated by 
coating the dye-loaded silica nanoaprticles with phospholipids membrane. The release was 
induced by the addition of the antimicrobial peptide cecropin (1-8)-melittin (1-18). The 
advantage of this system is the capability of adjusting drug release rate by external stimuli.  
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CHAPTER 1   INTRODUCTION 
 
1.1 Controlled Drug Delivery 
 
From the earliest times, people have found ways to introduce drugs into the body.  This 
process began with the chewing of leaves and roots of medicinal plants. Throughout the history of 
medicine delivery of drugs to humans has evolved from primitive extracts and inhalants to more 
reliable dosages forms, such as injections, tablets and capsules. These drug delivery systems are 
expected to be further optimized to increase drug activity and reduce toxicity. For instance, one of 
the most common ways of administering drugs to the body is via injection into the bloodstream. The 
injected material is circulated throughout the body and thus commonly termed systemic delivery. 
The drawbacks of this delivery method are that the concentration of the injected material is 
extremely diluted and the material acts on most tissues of the body and may be toxic to some of 
them. The problem could be solved by controlled drug delivery. In controlled drug delivery systems, 
the active agent is released in a predesigned manner.  Drug delivery systems can influence the 
performance of a drug by manipulating its concentration, location and duration of exposure. 
In the past 30 years, controlled drug delivery technology has represented one of the most 
rapidly advancing research areas [1-5]. The field is driven by the belief that controlled drug delivery 
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will contribute significantly to human health. These drug delivery systems offer numerous 
advantages compared to conventional dosage forms: 
♦ increasing the efficacy of currently used drugs 
♦ providing opportunities for the use of new agents currently precluded from clinical use due 
to challenges including low  drug solubility and systemic toxicity 
♦ reducing  harmful side effects 
♦ precise control of dose 
      ♦       decreasing number of dosages 
      ♦       improving patient compliance and convenience 
 
  
1.2 Strategy of Controlled Release 
 
There are three strategies to achieve controlled drug delivery. One method is to prepare 
drug delivery systems that release drugs over extended duration. Numerous works have been 
done based on biodegradable polymers [6-9]. In the conventional drug delivery, the drug 
concentration in the blood rises when drug is taken, then peaks and declines. Since each drug has 
a plasma level above which it is toxic and below which it is ineffective, the plasma drug 
concentration in a patient at a particular time depends on compliance with the prescribed routine. 
In contrast, with controlled release systems, the rate of drug release matches the rate of drug 
elimination. Therefore, the drug concentration is within the therapeutic range for a longer time.  
This release pattern is highly beneficial for drugs that are rapidly metabolized and eliminated 
from the body after administration.  
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The second approach is to prepare a feedback controlled devices that release the 
appropriate amount of drug in response to a therapeutic marker. In recent years, several research 
groups have been developing responsive systems [10-14]. These systems can be classified as 
external regulated and self-regulated systems. The external controlled devices apply external 
triggers for pulsed delivery such as: magnetic, ultrasonic, thermal and electric triggers. In the 
self-regulated system, the release rate is controlled by feedback information. The self-regulated 
systems utilize several approaches such as pH-sensitive polymers, enzyme substrate reactions 
and competitive binding, as rate-control mechanisms.  
             The third strategy is to control drug distribution in the body. The idea is to deliver a drug 
to the precise location in the body where it will be most effective. There are two basic types of 
targeting systems: passive and active. Passive targeting systems rely on non-specific interactions 
such as hydrophobic or electrostatic interactions, and the body physical characteristics. The size 
of drug carriers has been extensively studied for passive targeting. It was found that particles 
larger than 5-7 µm in diameter usually become trapped in the lung [15] and particles smaller than 
1 µm in diameter rapidly phagocytosed by the Kupffer cells of the liver [16]. When the particle 
size is reduced below 100 nm, the particles can appear in the bone marrow [17]. It was also 
demonstrated that drug carriers small than 200 nm can be accumulated efficiently in tumor 
through enhanced permeability and retention (EPR) effect due to the abnormality of tumor tissue, 
resulting in the enhanced vascular permeability compared to healthy tissues [18-20]. On the other 
hand, active targeting systems utilize specific interactions, such as antigen-antibody and ligand-
receptor binding, to achieve specific targeting goals. In this approach, the therapeutic index of 
drugs could be enhanced by keeping drugs away from healthy cells. The types of receptors that 
have been utilized for this purpose include transferrin receptors (tumor cells) [21], folate 
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receptors (tumor cells) [22], albumin receptors (cardiac and lung) [23] and growth factors 
receptors [24]. 
 
 
1.3 Scope of Controlled Drug Delivery Systems 
 
            While these fundamental ideas of controlled drug delivery are extremely attractive, 
achieving controlled drug delivery is not a simple or straightforward task. Currently, the vast 
majority of the work in this area is focusing on liposomes, micelles, drug conjugates, and 
particles. 
 
1.3.1 Liposomes and Micelles 
 
              Although liposomes were initially developed as models of biological membranes, their 
potential as a drug delivery system have undergone intensive investigations for over 25 years [25]. 
Liposomes are formed by the equilibration of natural phospholipids with excess water or aqueous 
salt solution. They contain one or several (concentric) lipid bilayers, which can solubilize 
hydrophobic drugs.  Alternating aqueous compartments can entrap hydrophilic drugs [26-29]. 
Liposomes with mean diameter smaller than 100 nm selectively spread in leaky tissues (eg. solid 
tumors), and exhibit target specificity with negligible adverse effects to normal tissues [30].  
            There are several advantages of liposomes as drug delivery carriers. Liposomes are able to 
protect drugs from degradation. They are relatively easy to prepare and prevent accumulation of 
drugs in normal organs which reduces their toxicity and improves pharmacokinetic effects (reduced 
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elimination, increased circulation life times). When coupled with antibodies, liposomes serve as a 
means to confer active targeting [31]. Some issues such as contents retention, circulation lifetime, 
biodistribution and immunogenicity can be managed by the formulation of the liposomal drug 
carriers [32-34]. Liposome properties such as size, surface charges, membrane rigidity and phase 
transitions within the bilayer can be controlled either by selecting appropriate lipid compositions or 
by changing external conditions such as temperature, acidity or the presence of specific agents [35-
39]. Liposomes have been used as carriers for many drugs with low molecular weight, peptides [40-
45] and oligonucleotides [46, 47]. However, liposomes also have limitations. One of the problems 
with liposomes as drug delivery carriers is their lack of stability in biological fluids. Consequently, 
drug molecules leak to normal tissues and cause undesirable side effects. 
Micellar drug carriers are formed from amphiphilic block copolmers composed of 
hydrophilic and hydrophobic segments. The hydrophobic segments form the inner core of the 
micelle and are surrounded by an outer shell consisting of the hydrophilic segments. Micelles are 
commonly of the order of 50 nm [48], which compares with the dimension of viruses, and thus may 
be able to penetrate the sinusoidal and fenestrated capillaries that have pores approximately 100 nm 
in size. However, micellar carriers are generally considered to be poor delivery systems because 
micellar complexes are in dynamic equilibrium with free molecules in solution. They continuously 
break down and reform, and they are generally unstable on dilution. 
 
1.3.2 Drug conjugates 
 
            The basic idea is to develop drug conjugates by chemically modify a drug in order to 
selectively alter properties such as: biodistribution, pharmacokinetics, solubility and antigenicity. 
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Thus, drugs have been attached to soluble macromolecules such as proteins, polysaccharides, and 
polymers via degradable linkages [49, 50]. This process changes the drug’s size and other properties, 
resulting in different pharmacokinetics and biodistribution.  One active area is to conjugate 
antitumor drugs to polymers. For example, doxorubicin, an antitumor agent was coupled to N-(2-
hydroxypropyl) methacrylamide copolymers, which resulted in radically altered pharmacokinetics 
and reduced toxicity. The half-life of the drug in plasma and the drug levels in the tumor were 
increased while the concentrations in the periphery decreased [51]. Polymers such as polyethylene 
glycol (PEG), can be attached to drugs to lengthen their lifetime. PEG-asparaginase is used for 
patients with leukemia [52]. Receptors such as transferrin were also used to conjugate antitumor 
agents for tumor targeting. Recently, dendrimers emerged as promising drug carriers. Compared 
with polymers, it is relatively easy for dendrimers to control molecular weight and functional groups. 
Recent studies showed that dendrimers attenuate the toxicity of approved drugs – methotrexate and 
6-mercaptopurine, suggesting that higher dosing might be attainable [53].   
 
 
1.3.3 Nanoparticle and microparticles 
 
The application of nanoparticles and microparticles as drug delivery systems has received 
increasing attention. They have been widely applied in the delivery of drugs, genes, and vaccines to 
specific cells and tissues of interest with potential reduction of toxicity as well as increased 
therapeutic effects [54, 55]. Compared to liposomes, particles appear to offer an interesting 
alternative. They possess higher stability in biological fluids and during storage. In addition, they 
have a larger loading capacity than liposomes. 
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           One of widely studied areas is polymer nanoparticles, either natural or synthetic, as drug 
carriers. Polymer particles have the ability to deliver a wide range of drugs to varying areas of the 
body for sustained period of time. The active agent can be released from polymeric systems by 
diffusion, degradation and swelling, depending on the nature of the polymer. The most common 
used polymers have been poly (lactic acid) (PLA), poly (glycolic acid) (PGA), poly (Є-caprolactone) 
(PCL) and the copolymer (PLGA) of PLA and PGA, These polymers are known for their 
biocompatibility and biodegradability [56]. The degradation rate and accordingly, the drug release 
rate can be manipulated by varying the polymer composition. Other than these polymers, natural 
hydrophilic polymers such as chitosan, sodium alginate and gelatin have also been used to prepare 
drug-loaded nanoparticles. These particles have shown good association with proteins, such as 
bovine serum albulmin, tetanus toxoid, diptaheria toxoid, insulin and oligonucleotides [57-59].  
Porous polymeric particles are also attractive as delivery systems due to their special 
structures. Langer et al developed a new type of inhalation aerosol, which is based on porous 
microparticles composed of 50:50 PLGA and poly (lactic acid-co-lysine-graft-lysine) [60]. Results 
revealed that inhalation of large porous insulin particles resulted in elevated systemic levels of 
insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin 
particles had this effect for only 4 hours. 
           Recently, advances in nanomaterials science and biotechnology facilitated the development of 
new drug delivery systems. Silica naoparticles are well known for their compatibility in biological 
system [61].  Their surfaces can be easily modified with different functional groups. These features 
make silica nanoparticles promising as drug carriers. Prasad et al demonstrated the potential of 
ceramic-based nanoparticles as drug carriers for photodynamic therapy [62]. Several other groups 
explored the potential of porous silica nanoparticles for controlled drug delivery due to their 
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attractive features such as large surface area, tunable pore sizes and surface properties [63-66]. Their 
research demonstrated that silica materials could play a significant role in developing a new 
generation of controlled drug delivery systems. 
 
 
1.4 Fluorescence and its Applications in Controlled Drug Delivery 
 
1.4.1 Fluorescence   
 
 Fluorescence is the property of some molecules and atoms to absorb light at a particular 
wavelength and to subsequently emit light of longer wavelength after a brief interval. 
Fluorescence typically occurs from poly-aromatic hydrocarbons or heterocycles molecules that 
are called fluorescent dyes or fluorophore. Fluorescence occurs when an excited molecule 
returns to the electronic ground state from the excited singlet state by the emission of a photon. 
Fig. 1.1 describes radiative and nonradiative processes that occur following excitation of 
a molecule.  S0, S1, S2, and Sn represent the singlet state of ground, 1st, 2nd, and nth electronic 
energy levels, respectively. T1, T2 represent the triplet states of 1st and 2nd electronic energy 
levels. The absorption of photons typically occurs from the lowest vibration level of S0 to a 
vibration state of S1 or S2. After the light was absorbed by the fluorophore, several processes take 
place. Nonradiative, fast relaxation brings the molecule down to the lowest excited state S1 
within 10-12 s. This process is defined as internal conversion. Fluorescence brings back the 
molecule to one of the vibronic sublevels of the ground state S0. The fluorescence lifetime of S1 
is generally in the range of 10-8 s. alternatively, collisional quenching may bring the molecule 
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back to its ground state without photon emission. A third type of process presenting in organic 
dyes is intersystem crossing to the first excited triplet state T1. Relaxation from this excited state 
back to the ground state is defined as phosphorescence. The lifetime of this state is in the order 
of microseconds to milliseconds. The entire fluorescence process is cyclical. Unless the 
fluorophore is irreversibly destroyed in the excited state, the same fluorophore can be repeatedly 
excited and detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Jablonski diagram illustrating the processes involved in the creation of an excited 
electronic singlet state by optical absorption and subsequent emission of fluorescence and 
phosphorescence. 
S0 
S2 
S1 
S3 
IC
ISC
hνA hνF hνP
IC
T1 
T2 
A = absorption 
F = emission of fluorescence  
P = emission of phosphorescence 
IC = Internal conversion 
ISC = Intersystem crossing 
 10
 
1.4.2 Applications in drug delivery 
 
        As we mentioned previously, the performance of a drug depends on its location, 
concentration and duration. Determining the drug biodistribution, cellular fate and cell uptake 
mechanism would enable better understanding of the cytotoxicity and the drug resistance. Mass 
spectroscopy is widely used to provide the information about drug delivery into specific organs 
and tissues.  However, it does not offer the information about cellular drug distribution. Imaging 
techniques are better choices for this purpose. Among them, fluorescence microscopy has been 
proven to be effective in studying the cellular fate of delivered drugs, due to its high sensitivity 
and easy-to-use procedure. For example, Savic and his coworkers prepared the 
tetramethylrhodamine labled PCL-PEO copolymer micelles. A triple-labeling confocal 
fluorescence microscopy was then developed to identify the location of the micelles [67]. Results 
revealed that the micelles were located in several cytoplasmic organelles, including 
mitochondria, but not in the nucleus. They also found that the micelles changed the cellular 
distribution and increased the amount of agent delivered into the cells.  
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CHAPTER 2: EXPERIMENTAL 
 
 This chapter described the general experimental information and instruments used to 
carry out the research work. Specific technical and experimental details will be described later in 
related chapter. 
 
 
2.1 Materials and Reagents 
 
Poly (DL-lactide-co-glycolide) (PLGA, L/G=50/50, inherent viscosity 0.17dL/g) (Birmingham 
Polymers, Inc.)   
Doxorubicin hydrochloride (Sigma) 
Polyvinylalchol (PVA) (average molecular weight 30000-70000 Da, 88% hydrolyzed) (Sigma) 
 3-(4, 5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Molecular Probes) 
Tetra ethyl orthosilicate (TEOS) (Sigma) 
Hexadecyltrimethylammoniun bromide (CTAB) (Fluka) 
Tetramethyl Rhodamine, Dextran 3000 (TMR-Dex) 
1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) (Avanti lipids) 
1,2-Didocosahexaenoyl-sn-Glycero-3-[Phospho-L-Serine] (Sodium Salt) (PS) (Avanti lipids) 
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Carboxyl Fluorescein (Sigma) 
Cecropin (1-8)-Melittin (1-18) hybrid peptide (CA (1-8)- M (1-18) ( Bachem America) 
Phosphate Buffered Saline tablet (Amresco) 
HEPES (Sigma) 
MES (Sigma) 
Dullbeco’s modified Eagle’s medium (invitrogen) 
Fetal bovine serum (invitrogen) 
Trypsin (invitrogen) 
Human breast cancer cell line (MCF-7) (American Type Culture Collection) 
Lab-Tek II chambered coverglass (Fisher Scientific) 
             All aqueous solutions were prepared with 18 MΩ deionized water produced by a water 
purification system (Barnstead Thermolyne nanopure) and all chemicals were used as received 
without further purification. 
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2.2 Procedures and Protocls 
 
2.2.1 Synthesis of PLGA and doxorubicin-loaded nanoaprticles 
 
 PLGA particles were prepared using a nanoprecipitation method [68]. Briefly, PLGA 
was dissolved in acetonitrile with concentrations range from 10 mg/mL to 17 mg/mL.  5 mL 
PLGA solution were then added dropwisely to a 15 mL PVA solution (1%) under magnetic 
stirring. The organic solvent was evaporated while being stirred first at atmospheric pressure 
overnight and then at reduced pressure for 2 hours. The particles were collected by centrifugation 
for 15 min and washed twice with deionized water to remove PVA residues. 
            For encapsulation of doxorubicin into nanoparticles, doxorubicin was dissolved in 
methanol and mixed with the PLGA solution (1:4, V/V), then added to the PVA solution. The 
procedure was repeated as described above. 
 
2.2.2 Synthesis of mesoporous silica nanoparticles  
 
           Mesoporous silica nanoparticles were synthesized based on a method developed by Cai 
and his coworker [69]. Typically, in a 500 mL flask, 0.5 g hexadecyltrimethyl-ammonium 
bromide (CTAB) was first dissolved in 240 mL deionized water. Then, 1.75 mL 2 M NaOH 
solution was added to the CTAB solution. The solution temperature was raised to 353 K while 
stirring.  When the solution became clear, 2.5 mL TEOS was added dropwisely to the surfactant 
solution. In 2min, the solution became cloudy.  The mixture was stirred at about 353K for two 
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hours.  After two hours, the particles were filtered out, washed with DI water and methanol, 
dried at ambient temperature. To remove the surfactant template, the resulting particles were 
refluxed in a solution of 160 mL methanol and 15mL 37% hydrochloric acid for 24 hours, 
filtered a second time and washed with DI water and methanol extensively. Then, the particles 
were dried with vacuum for 24 hours to remove the trace solvent remained in mesopore.  
 
2.2.3 Drug analog-tetramentylrhodamine dextran loading 
 
             To load the drug analog, 70 mg dried mesoprous silica particles were soaked in 1 mL 1 
mM TMR-Dex solution at pH 3 for 24 hours. Then, The TMR-Dex loaded silica nanoparticles 
were isolated by centrifugation at 12000rpm for 5min. The amount of TMR-Dex loaded was 
determined by monitoring the difference in the fluorescence of solution before and after 
absorption. Briefly, 10 µL free TMR-Dex solutions were taken from solution before and after 
absorption, respectively, and then diluted to 1 mL.  The difference was calculated using the 
calibration curve, which was obtained using standard TMR-Dex solution. All measurements 
were performed in triplicates. 
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2.2.4 Preparation of drug analog loaded silica with lipids coated (silica lipobeads) 
 
          To remove free dye, 250 uL TMR-Dex loaded silica nanoparticles suspensions were 
washed with pH 3 HCl solution and resuspended in 300 ul pH 5 solutions. To coat the TMR-Dex 
loaded silica nanoparticles, 1mL 25mM phospolipid chloroform solution were added dropwizely 
in particles suspensions while strongly vortexing. The resulting emulsion was dried under gentle 
nitrogen stream firstly to allow the phospholipids molecules absorb onto the surface of particles 
and then transfer to the vacuum for 6hours to remove organic solvent. Eventually, 5 mL 10 mM 
HEPES Buffer were added and stirred for 5 hours to form silica lipobeads. 
 
2.2.5 Cell culture 
 
             The human breast cancer cell line (MCF-7) was maintained according to protocol 
provided by ATCC. The cells were cultured at 37oC in a humidified atmosphere with 5% CO2. 
They were grown in Dullbeco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 1% Antibiotic-antimycotic, 4% L-glutamine, 1% sodium pyruvate, 1% 
non-essential amino acids and 0.01 mg/mL insulin. The medium was replaced three times a 
week. 
To prepare subcultures, Cell medium were removed from a cell culture plate and 5 mL 
trypsin were added. The cells in trypsin solution were incubated for 5-10 minutes and collected. 
The cell suspensions were centrifuged at 1700 RPM for 10 minutes. After trypsin was removed, 
the cells were resuspended in fresh cell medium and splited into new plates. Cell cultures on the 
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surface of a chambered coverglass were also prepared using the above procedure. The MCF-7 
cells were detached and placed in a chambered coverglass. Fresh cell medium was then added to 
chamber and the cells were incubated to attach and grow on the chambered coverglass overnight. 
 
 
2.3 Instrumentation 
 
2.3.1 Spectrofluorometry 
 
Emission spectra of free dye and dye-loaded naoparticles were obtained using a PTI 
model QM-1 spectrofluorometer (PTI, Quantmaster, Ontario, Canada). There are three major 
components in the system: Light source, monochromators and photomutiplier tube (PMT) 
detector. A 75-W high-pressure xenon (Xe) lamp is used as the excitation light source. Such 
lamps have a continuous and uniform intensity light output from 250 nm to 700 nm. Two 
monochromators are employed for selection of excitation and emission wavelength. The 
monochromators are autocalibrated and under computer control for scanning and positioning.  A 
vacuum PMT with the wavelength range 200-900 nm is employed as the detector. The PMT is a 
current source with the current being proportional to the light intensity. 
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2.3.2 Digital fluorescence imaging microscopy 
 
         The digital fluorescence imaging microscopy system, which is used for fluorescence 
measurement of particles and cell experiments are shown in Figure 2.1. The system consists an 
inverted fluorescence microscopy (Olympus IX-70) equipped with three detection ports. A 100-W 
mercury lamp is used as the light source. The fluorescence is collected by a 20x or 40x objective 
with a numerical aperture of 0.50, 0.90 respectively. Filter cube containing a excitation filter, a 
dichroic mirror and a emission filter was used to obtained the fluorescence images of particles and 
cells. A slow scan, high performance charged-coupled device (CCD) camera (Andor technology, 
Model DV 434) with a 1024 × 1024 pixel array is employed to collect digital fluorescence images of 
the drug containing- particles.  A PC-compatible microcomputer is employed for data acquisition 
using Roper Scientific software winspec 3.2.  The image ProPlus software was used for imaging 
analysis. 
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Figure 2.1 Digital Fluorescence Imaging Microscopy System 
 
 
2.3.3 Transmission Electron Microscopy 
 
          The size and morphology of particles were characterized using JEOL EM8291 electron 
microscopy. The operation voltage is 200 kV. 
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CHAPTER 3 TUMOR TARGETED DELIVERY OF 
ANTICANCER DRUG-DOXORUBICIN USING POLYMERIC 
NANOPARTICLES AS CARRIERS 
 
 
3.1 Introduction 
 
In the present study, we have entrapped the anti-cancer drug Doxorubicin (DXR) in poly 
(lactide-co-glycolide) PLGA nanoparticles and evaluated the cytotoxicity on MCF-7 cells. 
Doxorubicin (DXR) is one of the most widely prescribed antracycline agents.  It has been proven 
to be effective against variety of human malignancies, such as leukemia and breast cancer [70]. 
The mechanism of action of DXR has been extensively investigated. DXR is a DNA-
intercalating agent and a topo-isomerase inhibitor [71]. However, its use is restricted by 
problems associated with its cardio and systemic toxicity. To improve the therapeutic index of 
DXR, considerable interests have been drawn to develop submicron carriers-associated DXR 
formulation such as liposomes [72], micelles [73, 74], and nanoparticles [75-78]. PLGA is the 
most commonly used biodegradable polymer in drug delivery systems. It was approved by the 
Food and Drug Administration (FDA) in the United States. Also it’s a slow release polymer and 
often used to sustain a constant level of drug overtime. Yoo et al conjugated DXR with PLGA, 
then formed nanoparticles and achieved high drug loading. They showed maintained drug 
activity when comparing drug-conjugate with free drug [78]. In our study, we optimized the 
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conditions to prepare DXR-loaded PLGA nanoparticles and evaluated the potential of PLGA 
nanoaprticles as drug carriers for the delivery of doxorubicin into MCF-7 breast cancer cells. 
 
3.2 Specific Experimental and Technical Details 
 
3.2.1 Characterization of nanoparticles  
 
The Shape, surface and size of particles were characterized using Transmission Electron 
Microscopy (TEM) (JEOL EM8291). Samples were stained with 2% phosphotungstic acid, 
immobilized on copper grids and dried overnight for viewing.  Particle size and size distribution 
were analyzed by image ProPlus from TEM images taken from different fields. 
 
3.2.2 Fluorescence measurements 
 
Fluorescence spectra of DXR were measured using a PTI international (model QM1) 
fluorimeter.  A 75-W continuous Xe arc Lamp was used as a light source. Emission spectra of 
DXR were obtained with the excitation wavelength at 480 nm. 
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3.2.3. Loading studies of DXR 
 
DXR-containing nanoparticles were prepared by the method described in chapter 2.  
These nanoparticles were washed twice with DI water and collected by centrifugation at 4 oC. 
The amount of drug loaded was determined by analyzing the amount of drug present in 
supernatant. The supernatant concentration was calculated by measuring the emission at 590 nm 
with excitation wavelength 480 nm. All measurements were performed in triplicates. 
Encapsulation efficiency was calculated using formula shown below: 
% Encapsulation efficiency = (Total DXR- free DXR) /Total DXR 
 
3.2.4 In vitro drug release studies 
 
 The in vitro release studies of DXR from nanoparticles were carried out in phosphate 
buffered saline of pH 7.4 and pH 5 buffer solutions at 37oC. 1 mL DXR-containing nanoparticle 
suspensions were incubated in a water bath at 37 oC. At various time intervals, the supernatants 
were isolated by centrifugation for 15 min and their fluorescence spectrum was measured using 
the fluorimeter. The concentration of doxorubicin in the supernatants was calculated using 
calibration curves constructed using standard doxorubicin solutions in pH 7.4 and pH 5 buffer 
solutions. Samples were kept in the dark at all time. All samples were made in triplicates.  
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3.2.5 In vitro cytotoxic measurements 
 
         In vitro cytoxicity against the human breast cancer cell line MCF-7 was determined using 
tetrazolium dye (MTT) cell proliferation assay [79], which involved the conversion of 3-(4, 5-
dimethyl-2-yl )-2, 5-diphenyltetrazolium bromide into an insoluble formazan by metabolically 
active cells. MCF-7 cells were seeded into 96-well plates at a density 1×104 cells/well. One day 
later, the medium was removed and DXR-loaded PLGA nanoparticle suspensions were added to 
the wells.  The cultures were incubated with different concentration DXR-containing PLGA 
nanoparticles for 24 hours. After incubation, the cultures were washed three times with sterile 
PBS buffer and returned to incubator for a further 48 hours. Then, the cell medium was changed 
with 100ul fresh medium and 10µl MTT (5 mg/ ml in sterile PBS buffer) solution. These plates 
were reincubated for 4hours. The formed formazan crystals were dissolved in DMSO. The 
absorbance was measured at 540nm using a microplate reader. Cells grown in medium alone 
were used as a reference as 100% viability. All samples were made in sextuplicates. 
 
3.2.6 Cellular uptake studies by fluorescence microscopy  
 
 The cellular uptake of DXR-containing nanoparticles was studied using fluorescence 
microscopy. Briefly, MCF-7 cells were grown on coverslips for one day to adhere to the surface. 
The cell cultures were then incubated with DXR-containing nanoparticles at final concentration 
of DXR at 5 µM for 2 hours. After washed with PBS buffer, the cells were viewed by using a 
480/30x bandpass excitation filter, a 505 nm dichroic mirror and a 515nm longpass emission 
 23
filter. A slow scan, high performance charged-coupled device (CCD) camera (Andor technology, 
Model DV 434) with a 1024 × 1024 pixel array was employed to collect digital fluorescence 
images of the cells. 
 
 
3.3 Results and Discussion 
 
3.3.1 Characterization of PLGA nanopatricles 
 
        The ability of nanometric drug carriers to change the biodistribution and pharmacokinetics 
of drugs has been found in both vitro and vivo therapeutic applications. Among many factors, 
particle size and surface properties have been shown to be of primary importance in determining 
the pharmaceutical characteristics of these drug delivery systems. Administered particles of 
several micrometers in diameter for example, become entrapped within the lung capillaries. 
Smaller particles (< 200 nm) are unique in their ability to benefit from EPR effect and avoid 
spleen-filtering effects [80].   In the present study, PLGA nanoparticles were prepared, using an 
interfacial polymer deposition (nanoprecipitation) method based on the procedure previous 
reported by Fessi et al [68]. The PLGA copolymers assembled in aqueous media following 
precipatation from water-miscible organic solvent. Two different mean size particles (less than 
200 nm) were obtained by formulating nanoparticles with different polymer concentration 
(shown in Table 3.1).  TEM analysis revealed that all these particles had a dense, spherical 
morphology and size distribution is relatively broad (Fig.3.1).   A trend of increasing size with 
the increasing polymer concentration can be observed. The encapsulation efficiency increased 
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slightly with increasing polymer concentration. However, the encapsulation efficiency was less 
than 10% in both cases. The low drug loading was due to the hydrophilic nature of Doxorubicin 
hydrocloride. When drugs were added during the preparation process, they tend to diffuse into 
aqueous phase. 
 
3.3.2 Fluorescence studies 
 
           The inherent fluorescence of DXR was used to characterize the release properties, cellular 
uptake and intracellular distribution of drug-encapsulated nanoparticles. When excited at 480nm, 
DXR has fluorescence emission at 590 nm and 560 nm (Fig 3.2a). Fig 3.2b showed the 
fluorescence image of DXR- loaded PLGA nanoparticles. Clearly, we can see that DXR was 
entrapped in the nanoaprticles. The fluorescence spectrum of DXR-loaded PLGA nanoparticles 
was obtained by adding particles into the PBS solution to form the uniform suspension. Fig. 3.3 
showed the fluorescence spectra of DXR-loaded PLGA nanoparticles, free DXR and the released 
DXR from the nanoparticles. The emission spectrum of the released Doxorubicin was similar to 
that of free Doxorubicin.  This indicated that the encapsulation of doxorubicin in PLGA 
nanoparticles did not affect their structures and spectral properties.  The emission of Doxorubicin 
encapsulated in PLGA nanoparticles showed a change of the ratio between the two characteristic 
emission peaks of doxorubicin.   This could be attributed to the change in the chemical 
environment of doxorubicin when encapsulated in the particles.  
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Table 3.1 Nanoparticles formulation and characterization 
 
 Concentration of 
polymer (mg/mL) 
Particle size (nm) Encapsulation 
efficiency (%) 
a 17 182  8.8 ± 2.1 
b 10 110  6.2 ± 1.8 
 
 
 
Formulation a                                                        Formulation b 
 
Fig 3.1 Transmission electron images of PLGA nanoparticles (The samples were negatively 
stained.) 
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Fig. 3.2 a) Fluorescence emission spectra of DXR in PBS solution 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.2 b) Fluorescence image of DXR-loaded nanoaprticles . 
 
 
 
 
 
 
 
 
 
a
b
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Fig 3.3 Emission spectra of a) Released Doxorubicin from PLGA nanoparticles, b) free 
Doxorubicin    c) Doxorubicin encapsulated in PLGA nanoparticles. (The fluorescence 
intensities are not comparable since these samples do not have the same concentration.) 
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3.3.3 In vitro release Studies 
 
          The in vitro release profile of DXR was obtained at 37 oC by representing the percentage 
of released DXR with respect to the amount of DXR encapsulated in nanoparticles. Fig. 3.4 
showed the release profile of DXR loaded nanoparticles that were prepared with different 
polymer concentrations. The profiles exhibited initial burst release, followed by a slow release in 
both cases.  The release percentage of smaller particles was higher than that of larger particles. 
But the difference was not significant. Generally, there are mainly two release mechanisms from 
polymeric nanoparticles: diffusion through the microchannels that were formed during 
nanoparticles preparation and polymer erosion. In this system, the initial burst release effect is 
probably dominated by diffusion, rather than polymer erosion. 
              To examine the effect of pH on the drug release, we also performed the release studies 
in pH 5 buffer solutions keeping all of other conditions the same. At pH 5, the release rate was 
slightly enhanced (Fig 3.5). Around 18% and 15% drug content was released in 24 hours at pH 5 
and pH 7, respectively. The slight difference in release rate could be attributed to the enhanced 
solubility of drug at pH 5, since pH have an effect on the drug solubility due to its influence on 
the ionization of the drug. However, it must be noted that the difference between 18% and 15% 
in our experiments is too small to come to a clear conclusion. More studies are needed to better 
understand the effect of pH on drug release properties. 
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Fig 3.4 In vitro release profile of doxorubicin from PLGA nanoparticles (pH 7.4, 37oC)                  
 
 
 Fig 3.5 Release of Doxorubicin at different pH (polymer concentration 17 mg/ml, 37oC) 
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3.3.4 Cellular uptake and In vitro cytotoxicity studies 
 
Cellular uptake of DXR-loaded nanoparticles was evidenced by fluorescence microscopy 
(Fig 3.6). Fig 3.6a is the transmission image of intact cells, which were incubated with free DXR 
and Fig 3.6 b is the corresponding fluorescence image. Fig 3.6c and 3.6d are the images of cells, 
which were incubated with DXR-loaded nanoaprticles. These images were taken after 2hours 
incubation. It is interesting to note here, free DXR was localized within the cell nucleus and 
DXR-loaded nanoaprticles were localized in the perinuclear region. It could be evidence that 
DXR-loaded naoparticles were internalized through nonspecific endocytosis due to their small 
size. 
The cytotoxicity of DXR-loaded nanoparticles and free drug were tested against human 
breast cancer cell line MCF-7 by MTT assay [79]. Blank particles and untreated cell culture were 
used as control. Fig 3.7 showed cell viability after the cells were exposed to drug-containing 
nanoparticles with different concentration of DXR for 24 hours at 37oC under 5% CO2 
atmosphere. 
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Fig 3.6 Transmission images of MCF-7 cells treated with (a) free DXR (c) DXR-loaded PLGA 
nanoaprticles. Fluorescence images of (b) free DXR (d) nanoparticles. In image (b), the drugs 
were localized within the cell nucleus and in image (d) the drugs were localized in the 
perinuclear region. The cells were incubated with 5µM equivalent DXR concentration. All 
images were taken with 400x magnification. 
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Fig 3.7 The cytocoxicity of DXR-loaded PLGA nanoparticles (mean size 110nm)(    ) and free  
DXR (    ). The density of blank particles is the same as that of drug-load nanoaprticles. 
Untreated cell cultures were used as a reference as 100% viability. 
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As we can see in Fig 3.7, no cytotoxicity was observed when the cells were incubated 
with highest concentration of blank particles. But both drug-loaded nanoparticles and free drug 
showed concentration dependence cytotoxicity. In both cases, 50% inhibition of cell growth was 
achieved with around 2µM DXR (IC50). There is no significant difference about drug activity 
between drug-loaded particles and free drug, which indicated that the cytotoxicity of the drug has 
been maintained in the nanoparticles. 
Numerous studies aimed to develop DXR-loaded colloidal carriers. Some showed 
enhanced cytotoxicity of drug-loaded carrier compared to free drug [72, 73, 75]. Other studies 
like ours showed comparable cytotoxicity between drug-loaded carrier and free drugs [74, 76]. 
R. Tomlinson et al. conjugated DXR with polyacetal and in fact reported decreased cytotoxicity 
[81]. It seems that cytotoxicity of drug-loaded carrier is mainly affected by the rate of the cellular 
uptake and the nature of drug carriers, which determine the release properties in cells. 
Doxorubicin is a DNA-intercalating agent, which targets the cells nucleus. Generally, to travel 
through the nuclear pore complex, there are two mechanisms depending on molecular size. Small 
molecules (< 10 nm) can pass across the nuclear envelope by diffusion. Macromolecule and 
particles (< 25 nm) can only pass through by an energy-dependent process [82]. Therefore, to 
realize the cytotoxicity of drug-loaded carriers, which is usually larger than 25 nm, drugs must 
be released from carrier and diffuse into nucleus. The fact that our 110nm nanoparticles 
maintained drug activity suggested that the nanoparticles first attached and then encapsulated in 
cellular endosomes. The drugs are then released and diffuse into the cell nucleus. However, 
Further studies about determining subcellular drug distribution and delivery kinetics in real time 
have to be conduced to help us to understand the cytocoxicity . 
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3.4 Summary and Conclusions 
 
This study systematically evaluated the potential of PLGA nanoparticles as drug carriers 
for anticancer drug Doxorubicin for the first time. Doxorubicin was encapsulated into 
biodegradable PLGA nanoparticles by simple nanoprecipitation method. The size of particles can 
be changed by changing the polymer concentration. Fluorescence studies indicated that the 
encapsulation of doxorubicin in PLGA nanoparticles did not affect their structures and spectral 
properties. Therefore, we were able to characterize the release properties of system by 
fluorescence measurements. The release profiles showed that small particles had a higher release 
rate compared to larger particles. Fluorescence images indicated that these particles can be 
internalized by human breast cancer MCF-7 cells by non-specific endocytosis.  In vitro 
cytotoxicity study showed the drug activity of DXR-containing PLGA nanoparticles has been 
maintained. 
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CHAPTER 4 NOVEL SILICA NANOPARTICLES-BASED DRUG 
DELIVERY SYSTEM TRIGGERED BY ANTIMICROBIAL 
PEPTIDES 
 
 
4.1 Introduction         
 
       In recent years researchers in the field of drug delivery have attempted to induce 
drug release from drug carriers using physical or chemical stimuli [10-14]. For the most part the 
studies involved the use of liposomes [83-86].  Drug release from the liposomes was induced by 
a change in pH (83), temperature (84), light (85) and magnetic field (86).  Polymer nanoparticles 
were recently developed as alternative drug carriers to replace liposomes since liposomes often 
show limited capability as drug carriers (87).  Efficient drug loading into liposomes has proved 
difficult.  Additionally, drug molecules tend to leak out of liposomes prior to their localization in 
a targeted tissue.  This decreases the therapeutic efficiency and causes undesirable side effects.  
 
Recently, several groups explored the use of porous silica nanoparticles as drug delivery 
carriers [63-66].   Although silica particles are not biodegradable, the potential advantages of 
porous silica nanoparticles as drug carriers cannot be ignored.  First, it has been shown that silica 
nanoparticles are biocompatible [61].  Second, porous silica materials have a large surface area 
and therefore effectively host large amounts of drug molecules.  Furthermore, the pore size and 
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surface properties of mesoporous silica particles are easily controlled by changing conditions 
during their synthesis [88, 89].  Recent studies demonstrated that drug and protein molecules 
could be encapsulated with high loading efficiency in porous silica nanoparticles [63, 65, 90]. 
However, while the loading efficiency was indeed high the leakage rate of the encapsulated 
molecules was high as well.  A mechanism to minimize leakage of encapsulated molecules from 
porous silica particles and trigger the release by a chemical or physical stimulation is needed to 
facilitate their use as drug carriers.  
 
           In a recent study Lin and coworkers addressed the issue of minimizing leakage and 
triggered release from porous silica nanoparticles [66]. Following the encapsulation of ATP 
molecules in porous silica nanoparticles the pores of the particles were blocked by the covalent 
attachment of CdS nanocrystals to the surface of the particles.  This effectively blocked leakage 
of ATP from the particles. ATP release was then triggered by incubating the CdS capped silica 
particles in a solution that contained reducing agents like dithiothreitol and mercaptoethanol. Lin 
and coworkers showed that the CdS nanocrystals-coated silica nanoparticles did not affect the 
growth of astrocytes.  However, it is reasonable to expect that CdS nanocrstals would not be 
ideal plugs to contain drug molecules in porous silica particles.  Furthermore, the use of high 
levels of reducing agents to induce drug release in vivo may not be a viable option due to 
expected cytoxicity of the reducing agents themselves.  In this chapter we describe the use of a 
phospholipid membrane to block the release of drug molecules from porous silica nanoparticles 
(Fig. 4.1) and a new triggering mechanism, based on the use of low levels of antimicrobial 
peptides to induce drug release from these particles.  The advantages and limitations of this new-
triggered release technology are discussed. 
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4.2 Specific Experimental and Technical Details 
 
4.2.1 Characterization of silica nanoparticles 
 
The morphology and size of particles were characterized using Transmission electron 
microscopy (TEM). Specimens were prepared by dispersing the as-obtained powder in alcohol 
and then placing a drop of suspension on a copper grid coated with transparent graphite, 
followed by drying. Particles size and size distribution were analyzed by image ProPlus from 
TEM images taken from different fields. 
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Fig. 4.1.  Schematic representation of formation of phospholipid coated mesoporous silica 
nanoparticles as drug carriers. 
 
Adsorption Coated with lipids 
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4.2.2 Studies of TMR-Dex release profiles 
 
             The in vitro release studies of TMR-Dex from nanoparticles were carried out in 10 mM 
HEPES buffer solution. 17.5mg TMR-Dex loaded silica lipobeads were dispersed in 10mL 
buffer. The solution was sonicated for minute to obtain monodispersity. Then the suspension was 
divided into 1 ml ×10 aliquots. At various time intervals, 1 ml suspension was taken and the free 
TMR-Dex was washed by centrifugation for 5 min at 12000 rpm. The particles were then 
resuspended in 1 mL buffer solution and the fluorescence spectrum of the suspension was 
recorded using the fluorimeter. The retained percentage of TMR-Dex at various times was 
calculated by comparing the fluorescence intensity of the suspension at t = t’ and t= 0, where t’ 
represents aspecific time interval.  Samples were kept in the dark all the time. All samples were 
made in triplicates to enable quantitative data analysis.  
             To study the effect of temperature, the release was carried out in HEPES buffer solution 
at  pH 7.4 at room temperature and 42oC. 
 
4.2.3 The effects of antimicrobial peptide cecropin-melittin 
 
          The dependence of the %-released contents on peptide concentration was determined in 10 
mM HEPES buffer solution at pH 7.4.  Different amounts of cecropin-melittin were added to 500 
µL TMR-DEX loaded silica lipobeads. Then, the total volume was brought to 1mL by adding 
HEPES buffer solution. After 2hours, the free dye was removed by centrifugation and the 
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particles were resuspended in 1mL fresh HEPES buffer. The percentage of retained dye was 
calculated as described above. 
 
 
4.3 Results and Discussion 
 
4.3.1 Synthesis of mesoporous silica nanoparticles 
 
Silica nanoparticles are attractive candidates for many applications such as chemical 
sensing, ion-exchange coating and chromatography [91]. Extensive studies were carried out 
using silica materials which were prepared by the sol-gel process.  In a typical sol-gel process, 
tetraalkylsilane is mixed with water followed by the addition of catalyst. Tetraalkylsilane can be 
hydrolyzed and condensed to form the sol and the sol is further crosslinked through 
polycondensation to form a rigid, porous network-gel. However, the limitation of sol-gel 
materials is their variability in pore size, which cannot be tailored for specific molecules. 
Discovery of mesoporous silica materials made it possible to tailor both pore size and structure 
of these materials for specific hosts. Mesoporous silica materials are synthesized by self-
assembly of silica-surfactant in which inorganic species simultaneously condense, giving rise to 
mesoscopiclly ordered composites formation [69, 92]. Well-defined pore size depends mainly on 
the surfactant, which is employed as a template in the synthesis. In our study, mesoprous silica 
nanoparticles were synthesized using a method developed by Cai [69].  TEM images revealed 
that the average size of nanoparticles was around 90 nm with narrow size distribution. The 
particles exhibited elongated sphere morphology (Fig 4.2).   
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Fig. 4.2  (A) TEM (B) Fluorescence images of TMR-DEX loaded silica nanoparticles. The 
average size of the nanoparticles was around 90 nm. 
 
 
4.3.2 Loading studies of TMR-Dex into silica nanoparticles 
 
         To easily monitor the drug- loading and release properties of the particles, we chose the 
fluorescent dye-tetramethylrhodamine dextran (3000Da)(TMR-Dex), which has high extinction 
coefficient, stability and pH insensitivity, as a drug analog. To load the dye into the particles, 
mesoporous silica nanoparticles were dispersed in TMR-Dex solution at pH 3 for 24 hours. 
Electrostatic attraction between the protonated TMR-Dex due to the acidic conditions and the 
negatively charged silica enhanced the entrapment efficiency of TMR-Dex in the silica particles. 
The dye content in the particles was measured by monitoring the difference in the fluorescence 
of the preparation solution prior and following dye entrapment into the particles. The loading 
efficiency was about 28±2%.  However, TMR-Dex molecules diffused out of the particles under 
physiological pH conditions due to decreasing electrostatic attraction forces.   
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4.3.3 Lipids membrane coating of TMR-DEX-loaded silica nanoparticles 
 
Liposomes were extensively studied for drug delivery and chemical sensing. They have a 
flexible, cell-like lipid bilayer surface, which acts as a permeability barrier such that compounds 
can be entrapped in their aqueous interior. However, liposomes can be mechanically unstable 
and their loading capacity is relatively low compared to solid particles. Previously, lipid bilayers 
supported on various solid surfaces, such as glass [93], plastic [94], and metal [95] as well as 
modified polymers [96] have been shown to provide a stable and well-defined cell-membrane-
like environment. Based on this knowledge, several groups proposed hybrid vesicle systems, 
which have polymer nanoparticles as core and lipid bilayer as shell [97-100], termed lipobeads. 
In our group, lipobeads were used for intracellular sensing [99,100]. Our studies showed that the 
phospholipid membrane protected sensing elements from cellular environment.  
The objective of our study was to realize stable drug containing nanoparticles that only 
release their content instantly when stimulated.  To this end the particles were coated with a 
phospholipids membrane using a procedure previously developed in our laboratory for the 
fabrication of lipobead-based nanosensors. The silica lipobeads were washed several times to 
remove dye molecules that leaked out of the particles prior to applying the phospholipid 
membrane and re-adsorbed to the membrane following the formation of the membranal coating.  
Temporal release profiles shown in figure 4.3 indicate that the phospholipids membrane 
efficiently blocked leakage of dye molecules from the silica lipobeads.  Almost 95% of the 
TMR-Dex retained in phospolipid coated silica nanoparticles over 12 hours.  In contrast, about 
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90% of the TMR-Dex molecules leaked from uncoated silica matrix in 12 hours following their 
preparation.  
To examine the effect of temperature, the release experiment also carried out at 42 oC 
with silica DMPC-lipobeads.  We expected an increased release since DMPC had a phase 
transition at 24 oC [101]. Above the phase transition temperature, lipid bilayers undergo a change 
in structure, switching from a gel state where acyl chains of the lipids molecules are closely 
organized, to a sol state where the acyl chins are disorganized. Therefore, the lipid bilayer is 
more fluid.  Surprisingly, the release was the same as that of room temperature within 4 hours 
(Fig. 4.4). After this time, the release increased rapidly. The possible reason is that the TMR-Dex 
molecule were too large to pass through bilayer membrane even at sol state. But overheating 
(longer than 4 hours) could destabilize the lipid membrane. The same experiments were carried 
out when the particles were coated with DPPC lipid. Similar results were observed. 
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Fig. 4.3  Release profile of TMR-Dex loaded silica particles in 10mM HEPES pH7.4 buffer 
solution. 
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Fig. 4.4 Release profile of TMR-Dex loaded silica DMPC-lipobeads in 10mM HEPES pH7.4 
buffer solution at 42oC.
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4.3.4 The induced release of TMR-DEX by antimicrobial peptide 
 
As mentioned previously, the development of drug carriers that effectively encapsulate 
the drug with minimal leakage and only release it when triggered chemically or physically would 
be highly beneficial to many clinical situations.  The selection of an appropriate triggering 
strategy is crucial.  For example, pH- sensitive drug carriers would release their content as a 
result of a pH change in a tissue.  In many cases the pH required for effective release is 
unreachable.  Similarly, drug carriers that rely on temperature changes to induce release are 
limited because of the narrow temperature range under physiological conditions and the 
relatively wide range of body temperature of normal patients. In this study we explored the use 
of low concentrations of antimicrobial peptides to induce the release of our fluorescent drug 
analog TMR-Dex from the silica lipobeads.  Antimicrobial peptides are a group of small peptides 
that show a broad range of activity against Gram-negative and Gram-positive bacteria, fungi, 
mycobacteria and some enveloped viruses [102].  These peptides attracted increasing attention in 
recent years since they represent a promising new alternative for conventional antibiotic drugs.  
These peptides could provide a solution to the growing problem of antibiotic resistance [102].  
The mechanism of action of these peptides involves increasing cell membrane permeability 
either by forming aqueous channels which span the membrane bilayer or by disrupting 
membrane organization [102,103].   We predicted that antimicrobial peptides could disrupt the 
membranal coating of the silica lipobeads to facilitate the release of TMR-Dex from the 
particles.  To test this triggered release strategy, our TMR-Dex containing lipobeads were 
incubated with solutions of the antimicrobial peptide- Cecropin A(1-8)-Melittin(1-18) hybrid. 
The phospholipids membrane of the silica lipobeads was composed of 1,2-Dimyristoyl-sn-
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Glycero-3-Phosphocholine (DMPC). Temporal release profiles of TMR-Dex silica lipobeads 
upon addition of antimicrobial peptide are shown in figure 4.5.  Curve a shows a control 
experiment in the absence of the peptides in which no release is seen, indicating that the 
membrane remained intact throughout the experiment.  Curves b shows that the release was 
rapidly triggered after the addition of 0.175 mg/mL Cecropin A-Melittin. About 70% of dye 
contents were released. Also, the dependence of the %-released contents on peptide 
concentration was studied. As Fig. 5 showed, a maximum release was obtained at 0.350mg/mL 
peptides and minimum peptide concentration 0.044mg/mL was required to induce the release 
effectively.  
The effect of Cecropin A(1-8)-Melittin(1-18) hybrid on the negatively charged 
phospholipids Bovine brain phosphatidylserine (PS) coated silica particles was also tested. As 
Fig.4.6 and 4.7 showed, the cecropin A-melittin is more effective on the negatively charged PS 
lipobeads than on the neutral DMPC lipobeads.  This may result from the cationic nature of the 
peptide at pH 7. Further studies about dependence of the %-released contents of PS lipobeads on 
peptide concentration are in progress. 
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Fig. 4.5 Release profiles of silica DMPC-lipobeads treated with 0.175 mg/mL Cecropin A-
melittin peptide. 
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Fig. 4.6 Peptide concentration-dependent release. (The measurements were taken 2 hours after 
addition of cecropin-melittin peptide). 
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Fig. 4.7 Fluorescence spectra of silica DMPC-lipobeads (Measurements were taken 2 hours after 
peptides were added) 
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Fig. 4.8 Fluorescence spectra of silica PS-lipobeads (Measurements were taken 2 hours after 
peptides were added) 
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4.4 Summary and Conclusions 
 
In summary, we have developed a novel silica nanoparticles-based drug delivery system, 
which enables high drug loading and regulated drug release by adjusting the level of an adjuvant 
drug.  While this approach show clear advantages over physical stimulation like temperature 
change or other non-selective and unregulated pH changes the toxicity of antimicrobial peptides 
still remained a concern.  Future work is in progress to seek a lipid membrane which would be 
selectively destroyed by peptides that do not harm living cells. 
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CHAPTER 5 SUMMARY AND CONCLUSIONS 
 
 
Controlled drug delivery can influence the performance of a drug by manipulating its 
concentration, location and duration. Therefore, it provides a promising way to minimize side 
effects and increase therapeutic efficacy. In the past decades, controlled drug delivery technology 
has represented one of the frontier areas of science, which involves multidisciplinary scientific 
approach. This thesis describes the development and characterization of new nanoparticles-based 
drug carriers with unique release properties. 
Chapter 3 describes the development of a polymeric nanoparticle-based drug delivery 
system for the anticancer drug doxorubicin. Biodegradable poly (lactide-co-glycolide) (PLGA) 
particles of various sizes were prepared by changing the polymer concentration. Transmission 
electron microscopy (TEM) images revealed that the particles had smooth spherical morphology 
with a mean size ranging from 110nm to 180nm. The in vitro release profile showed that small 
particles (110nm) had a higher release rate compared to larger particles (180nm). For all 
nanoparticles prepared with different polymer concentration, an initial burst release, followed by 
a slow release, were observed. These results indicated that the drugs were released through a 
diffusion-controlled release mechanism.  Fluorescence imaging studies showed that the 
nanoparticles could be internalized by MCF-7 human breast cancer cells. Interestingly, different 
intracellular distribution of free drugs and the drug-loaded nanoaprticles were observed. It 
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indicated that they were taken up by different mechanism. Probably free drugs were taken up by 
diffusion and nanoparticles were internalized by non-specific endocytosis. The bioactivity of the 
drugs was also tested against MCF-7 cell culture. In vitro cytotoxicity study showed that drug 
activity had been maintained in these particles. 
In Chapter 4, we reported the preparation of mesoporous silica nanoparticles and their use 
in triggered drug release system. Silica nanoparticles, which can be prepared with a desired size, 
tunable pore size and surface properties, were previously used as hosts of proteins and catalysts.  
We loaded the mesoporous silica nanopartilces with the tetramethylrhodamine dextran (TMR-
Dex), which was used as a fluorescent drug analog.  We then coated the nanoparticles with a 
phospholipid membrane to seal drug molecules inside the nanoparticles. Temporal 
release profiles showed that 95% of the TMR-Dex molecules were retained in phospholipids 
coated silica nanoparticles over 12 hours.  In contrast about 90%of the TMR-Dex molecules 
leaked from uncoated silica particles during the same time period.   The release of TMR-Dex 
molecules from phospholipids coated silica particles was triggered by adding the antimicrobial 
peptide cecropin-melittin to the particle suspension. About 70% of TMR-Dex molecules were 
released in 2 hours following the addition of 0.175mg/mL cecropin-melittin (final 
concentration). The regulated release of the encapsulated content was realized by adjusting the 
level of the antiimicrobial peptide cecropin (1-8)-melittin (1-18). Further studies will focus on 
optimizing the composition of lipids membrane to selectively destroy the coating without 
inducing toxicity to living cells. 
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